Objectives
The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development.
The objectives of the SIG are:
- To share (anonymized) case studies of how quantitative decision-making methods have been used within pharmaceutical companies, for decisions at the trial level, at the development level and at the portfolio level
- To perform literature reviews, discuss and make recommendations on existing methodologies in terms of approach and interpretation
- To develop new methodologies or practices where needed
- To promote the role of the statistician in supporting decision-making in pharmaceutical companies and/or other stakeholders
- To propose trainings, public meetings or publications to share methods and experience
Who we are
| Gianluca Baio (UCL) |
| Nicolas Bonnet (Sanofi) |
| Sarah Bray (Amgen) |
| Alex Carlton (GSK) |
| Jacquie Christie (GSK) |
| Pierre Colin (Debiopharm) |
| Paul Frewer (AstraZeneca) |
| Heiko Goette (Merck) |
| Martin Johnson (UCB Pharma) |
| Kevin Kunzmann (Cambridge University) |
| John-Philip Lawo (CSL Behring) |
| Jesper Madsen (Novo Nordisk) |
| Pavel Mozgunov (Lancaster University) |
| Emmanuel Pham (Ipsen) |
| Veronique Robert (Servier) |
| Oliver Sailer (Boehringer Ingelheim ) |
| Gaëlle Saint-Hilary (Servier) (Chair) |
| Guido Thömmes (Grunenthal) |
How to get in touch
For further information, or to join the QDM SIG, please contact the chair:
Gaelle Saint-Hilary (Servier and Politecnico di Torino)
gsainthilary@gmail.com
Latest News
...
Upcoming Events
...
